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 ABSTRACT 
 
Objectives:  To develop methods for mapping to preference-based measures using mixture model 
approaches. These methods are compared to map from the Asthma Quality of Life Questionnaire 
(AQLQ) to both EQ5D-5L and HUI-3 as the target health utility measures in an international dataset.   
Methods: Data from 856 patients with asthma collected as part of the Multi-Instrument Comparison 
(MIC) international project were used. Adjusted limited dependent variable mixture models 
(ALDVMMs) and beta-regression based mixture models were estimated.  Optional inclusion of the 
gap between full health and the next value, and a mass point at the next feasible value were explored. 
Response-mapping could not be implemented due to missing data.  
Results: 
In all cases, model specifications which formally modelled the gap between full health and the next 
value were an improvement on those which did not.  Mapping to HUI3 required more components in 
the mixture models than mapping to EQ5D-5L due to its uneven distribution.  The optimal beta-based 
mixture models mapping to HUI3 included a probability mass at the utility value adjacent to full 
health.  This is not the case when estimating EQ5D-5L, due to the low proportion of observations at 
this point. 
Conclusion: 
The beta-based mixture models marginally outperformed ALDVMM in this dataset when comparing 
models with the same number of components. This is at the expense of requiring a larger number of 
parameters and estimation time.  Both model types are able to closely fit the data without biased 
characteristic of many mapping approaches. Skilled judgment is critical in determining the optimal 
model. Caution is required in ensuring a truly global maximum likelihood has been identified.  
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INTRODUCTION  
Preference-based outcome measures (PBMs) that allow the calculation of health state utilities are not 
always administered in studies of clinical effectiveness.  However, these outcomes are often preferred 
by decision makers in order to estimate quality-adjusted life-years (QALYs) for use in cost-
effectiveness analysis.  ‘Mapping’, or ‘cross-walking’, is commonly used to estimate health state 
utilities when clinical studies have not included any preference based measure (1).    
There are two broad approaches to mapping. The direct approach models the health state utility values 
themselves. The indirect approach, also referred to as response-mapping, models each dimension of 
the PBM and calculates the predicted utilities as a second, separate step. Response-mapping models 
require observations (preferably a sizeable number) at all levels of each dimension and this can be a 
problem for small datasets if there are many different levels in each dimension.  
Health state utility values are characterised by unusual distributions; they are commonly skewed, 
multi-modal, often have a large number of observations at 1 (indicating full health) and a gap between 
full health and the next feasible value. By definition, they are limited between the range of best and 
worst health states.  Basic regression models are unable to capture all these features which leads to 
biased estimates of health gain.  
Beta regressions can provide flexibility when modelling skewed, bounded PBMs.  Basu & Manca 
proposed the use of single and two-part beta regressions to model PBMs and QALYs(2).  The 
standard beta regression assumes that the dependent variable is only defined in the open interval (0,1) 
but many PBMs  display negative values.  Some studies have suggested that a beta regression is 
inappropriate in these cases(3).  Other studies have attempted to overcome this problem by converting 
ad hoc all negative values to zero(4,5) not only ignoring that some health states are worse than death 
but potentially distorting the distribution due to the well-known sensitivity of beta regressions to pile-
ups of values at the boundaries.  However, there is a standard transformation1 in the literature which 
allows the transformation of values in any open interval into a (0,1) interval(6). After estimation, the 
expected value is then transformed back to its original scale to obtain the correct predictions. In the 
area of mapping, this is the approach followed by Kent et al. and Khan et al.(7,8).  Beta-based 
regression models have been found to be more robust and outperform linear regressions(2,8,9).  One 
significant issue when using beta regressions is how to deal with observations on the boundaries of 
the feasible utility range. Different methods have been proposed and it is recommended that the 
sensitivity of the estimates to the different methods is assessed(6).  Even though beta regressions can 
deal with the bounded nature of utility data and can reproduce a variety of shapes, multimodality is 
difficult to capture. 
Mixture models are increasingly being used in the context of mapping because of their flexibility and 
the ability to capture multimodality(2–6,10,11). Mixtures of normal distributions have been used to 
model different PBMs such as HUI3(12), EQ-5D-3L(7,9) and SF-6D(9). Some mixture models have 
been specifically designed for utility mapping such as the adjusted limited dependent variable mixture 
model (ALDVMM)(10,11,13,14).  This employs a mixture of adjusted normal distributions to account 
for the multimodality of PBMs and includes a number of other useful characteristics.  It contains 
built-in features which account for the peak of observations at full health and the option of a- gap in 
the distribution below that peak.  Other mixture models used for mapping include a mixture of Tobit 
models censored to account for the bounded nature of PBMs with an additional degenerate 
distribution at perfect health(15).  One additional study(8) claims to estimate a limited dependent 
variable model. However, the model described is not a finite mixture model but a two-part model with 
an ad-hoc assumption of a normal distribution for values of the dependent variable below 0.3 and a 
                                                     
1 𝑦𝑦′ = (𝑦𝑦 − 𝑎𝑎)/(𝑏𝑏 − 𝑎𝑎) for the interval [a,b]. 
beta binomial for values at or above. The split at 0.3 is justified via visual inspection of a kernel 
density plot of the dependent variable.  Recently, beta mixture models have also been used in utility 
mapping with success(7). In general, mixture models have been found to outperform non-mixture 
models(13–15).  One study found some evidence to suggest that beta regression can outperform 
mixture models which might be in part related to the distributional shape of the health utility measure 
being used(9). 
This study develops knowledge about mapping methods by comparing approaches for estimating two 
PBMs, EQ5D-5L and HUI3, from the Asthma Quality of Life Questionnaire Sydney (AQLQ-S) 
score, a clinical asthma measure using data from an international sample(16).  Two different classes 
of mixture models are used: the ALDVMM  and extensions to the beta mixture model in Kent et al 
which a) account for the gap in the PBM distributions between full health and the next feasible value 
and b) allow alternative approaches to deal with observations on the boundary of the beta 
distribution(7). 
All models are estimated using user-written code in Stata via the commands ‘aldvmm’(13) and 
‘betamix’(17). 
 
METHODS 
Data 
We used data from the Multi Instrument Comparison (MIC) project dataset which includes data on 
7,933 observations across 6 countries: Australia, Canada, Germany, Norway, the UK and the 
USA(16).  The data include information on wellbeing, health state utilities and demographics.  In 
addition, respondents who self-reported having specific conditions were asked to answer disease 
specific questionnaires.  In total, 856 respondents self-reported asthma and completed the AQLQ-S 
questionnaire.  Data were available for respondents’ age and sex as well as their EQ5D-5L and HUI3 
scores.  After removing observations with missing values in any of the required variables, the final 
sample for analysis was 852. 
Preference Based Measures 
Both EQ5D-5L and HUI3 are PBMs with health state utilities estimates for each feasible response to 
their descriptive system.  EQ5D-5L covers the same 5 dimensions as the original 3-level version 
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression) but each dimension has 
5 response levels (no problems, slight, moderate, severe, extreme/unable to do).  It is designed for 
self-completion, has a low response burden and is applicable to a range of diseases and treatments.  
HUI3 is also a self-completion questionnaire with 8 dimensions (vision, hearing, speech, ambulation, 
dexterity, emotion, cognition and pain).  The levels for each dimension vary between 5 and 6. We use 
the value sets in Devlin et al(18) and Furlong et al(19) to attach utility values to each health state in 
EQ5D-5L and HUI3, respectively.  For both instruments, a value of 1 represents full health, a value of 
0 is considered equivalent to being dead and their values can be negative, representing a state worse 
than death.  Both instruments have a gap between full health and the next feasible health state (0.951 
in EQ5D-5L and 0.97258 in HUI3).  We refer to this value as the truncation point. The lower limits 
are -0.281 and -0.36 respectively for EQ5D-5L and HUI3. 
AQLQ 
The Sydney Asthma Quality of Life Questionnaire (AQLQ-S) was designed as a measure of quality of 
life for adult patients with asthma.  The questionnaire contains 20 questions within 4 domains 
(symptoms, activity limitation, emotional function and environmental stimuli).  Each of the questions 
allows a response on a 0-4 scale, with 0 representing no problems at all.  The scores for each question 
are averaged to produce an overall AQLQ-S score between 0 and 4.  Although there are many 
different versions of the AQLQ, the AQLQ-S is recommended by the European Medicines Agency 
(EMA)(20) and has been validated(21).  However, because the scoring is not preference-based, it is 
not suitable for use in cost-utility analysis.  
Statistical Methods 
It was not feasible to conduct response-mapping since this requires observations in each response 
category of the different dimensions covered by the target descriptive system. In the case of EQ-5D, 
there are no observations with the worst possible response for self-care.  For HUI, there were no 
observations with the worst possible response for vision.   
We compared two approaches to direct mapping, both based on mixture models.  The first is an 
adjusted limited dependent variable mixture model (ALDVMM) implemented using the publicly 
available Stata command ‘aldvmm’(13).  This model has previously been applied for mapping across 
a range of clinical areas, including rheumatoid arthritis(13,14), osteoarthritis(22), ankylosing 
spondylitis(23) and traumatic brain injury(24). It has been shown to outperform other methods (linear 
regression, Tobit and response-mapping).  The ALDVMM is a bespoke model developed specifically 
for utility mapping and the Stata function includes a number of user-specified options to tailor the 
method to the target utility instrument and country specific tariff of interest. This includes specifying 
the next feasible value after full health(13), the “truncation point”, thus creating the typical gap seen 
in PBMs. There is the option to specify no truncation and therefore allow each component of the 
mixture model to be fully continuous up to the highest feasible value of 1 for full health. The method 
has previously been described in detail(14). In brief, ALDVMM is a mixture of adjusted, normal 
distributions for use when the dependent variable is limited above at 1 (full health) and below, in this 
case at -0.205 for EQ5D-5L and -0.36 for HUI3.  As well as estimating the model with different 
numbers of components, we also estimated it with and without truncation. 
The second model we used is a beta-based mixture model estimated via the user-written Stata 
command ‘betamix’(17) which is a generalisation of the truncated inflated beta regression model 
introduced in Pereira et al(25).  This is a two-part model consisting of a multinomial logit model and a 
beta mixture model. A beta distribution cannot deal with observations at the boundaries because the 
log-likelihood is undefined at these points. The addition of the multinomial logit model to the beta 
mixture allows for these observations and a mass of observations at full health.  The model assumes a 
limited dependent variable 𝑦𝑦𝑖𝑖 for each individual 𝑖𝑖 defined at point  1 and the interval [𝑎𝑎, 𝜏𝜏] where 
𝑎𝑎 <  𝜏𝜏 < 1 and can be written as 
 
𝑔𝑔(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖1,𝑥𝑥𝑖𝑖2, 𝑥𝑥𝑖𝑖3) =
⎩
⎪
⎨
⎪
⎧
𝑃𝑃(𝑦𝑦𝑖𝑖 = 𝑎𝑎|𝑥𝑥𝑖𝑖3),                                          𝑦𝑦𝑖𝑖 = 𝑎𝑎
𝑃𝑃(𝑦𝑦𝑖𝑖 = 𝜏𝜏|𝑥𝑥𝑖𝑖3),                                                  𝑦𝑦𝑖𝑖 = 𝜏𝜏
𝑃𝑃(𝑦𝑦𝑖𝑖 = 1|𝑥𝑥𝑖𝑖3),                                                  𝑦𝑦𝑖𝑖 = 1
�1 − � 𝑃𝑃(𝑦𝑦𝑖𝑖 = 𝑠𝑠|𝑥𝑥𝑖𝑖3)
𝑠𝑠=𝑎𝑎,𝑏𝑏,𝜏𝜏 � ℎ(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖1, 𝑥𝑥𝑖𝑖2), 𝑦𝑦𝑖𝑖 ∈ (𝑎𝑎, 𝜏𝜏)
 (1)  
with probabilities 
 
𝑃𝑃(𝑦𝑦𝑖𝑖 = 𝑘𝑘|𝑥𝑥𝑖𝑖3) = exp (𝑥𝑥𝑖𝑖3′ 𝛾𝛾𝑘𝑘)1 + ∑ exp (𝑥𝑥𝑖𝑖3′ 𝛾𝛾𝑠𝑠)𝑠𝑠=𝑎𝑎,𝑝𝑝,𝑏𝑏  (2)  
where 𝑥𝑥𝑖𝑖3 is a vector of variables influencing the probabilities, 𝛾𝛾𝑘𝑘 is a vector of coefficients and 𝑠𝑠 
refers to each section of the distribution.  For identification, the coefficients corresponding to the 
continuous part of the distribution are set to zero.  The probability density function for the continuous 
part of the distribution has probability density function ℎ(. ) made up of a mixture of C-components 
each representing a beta distribution, with mean 𝜇𝜇𝑐𝑐𝑖𝑖 and precision parameter 𝜙𝜙𝑐𝑐, 𝑐𝑐 = 1, … ,𝐶𝐶, such 
that 
 
ℎ(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖1, 𝑥𝑥𝑖𝑖2) = �(𝑃𝑃(𝑐𝑐|𝐶𝐶
𝑐𝑐=1
𝑥𝑥𝑖𝑖2)𝑓𝑓(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖1𝛽𝛽𝑐𝑐 ,𝜙𝜙𝑐𝑐 ,𝑎𝑎, 𝜏𝜏)) (3)  
where 𝑓𝑓(. ) is a beta density with alternative parameterisation and 𝐶𝐶 is the number of components 
included in the analysis.  Component membership is determined using a second multinomial logit 
model, such that 
 
𝑃𝑃(𝑐𝑐|𝑥𝑥𝑖𝑖2) = exp (𝑥𝑥𝑖𝑖2′ 𝛿𝛿𝑐𝑐)∑ exp (𝑥𝑥𝑖𝑖2′ 𝛿𝛿𝑗𝑗)𝐶𝐶𝑗𝑗=1  (4)  
where 𝑥𝑥𝑖𝑖2 is a vector of variables influencing the probability of component membership and 𝛿𝛿𝑐𝑐 is a 
vector of corresponding coefficients.  Again, one set of coefficients is set to zero for identification. 
The model is not constrained to the (0,1) range but transforms values to the relevant interval for the 
target utility instrument (-0.281 to 1 for EQ5D-5L and -0.36 to 1 for HUI). It is capable of producing 
estimates at either of the feasible limits, though for health utilities this is most relevant for mass points 
at full health (1). As with the ALDVMM, betamix also allows the specification of a gap between full 
health and the next feasible health state and for a mass of observations at this truncation point.  
Although it is possible to include a probability mass at the lower utility limit, for both model types, 
we did not include this here because our sample contained no observations with values at the lower 
utility limit for either PBM. 
We estimated different specifications of each model type, with different numbers of components and 
with and without probability masses at certain points of the distribution. We included AQLQ-S 
summary score, age, age-squared and sex as covariates in all parts of the model.  For each of the 
models we are able to use simulated data to create figures showing the conditional distribution 
functions for each of the models. 
Preferred models were selected using a variety of fit statistics: Akaike and Bayesian Information 
Criteria (AIC and BIC), root mean squared error (RMSE), mean absolute error (MAE) and mean error 
(ME). We assessed fit across the distribution of disease severity.  We compare the conditional 
distribution function of the observed data with the one derived from the estimated model. This builds 
on previous work in the area which focus on the summary measures(5).  In many cases these criteria 
each support different models and so judgement must be used in determining the preferred model.   
RESULTS 
The final sample consisted of 852 observations (see Table 1) of which 62.3% were female.  Age 
ranged from 18 to 89 years. Whilst the AQLQ spanned the entire range of feasible values (0-4), 
neither EQ5D-5L or HUI3 did.  
Figure 1: Distribution of a) EQ5D-5L and b) HUI3 
  
a) EQ5D-5L b) HUI3 
 
Figure 1a and 1b show the distributions of EQ5D-5L and HUI3, respectively.  Both HUI3 and EQ5D-
5L exhibit mass points at the upper full-health limit: 20.9% in EQ5D-5L and 9.5% in HUI3.  For 
EQ5D-5L, there was no significant mass of observations at the truncation point (0.951). Almost 6% of 
observations were at the HUI3 truncation point (0.973).  There were a relatively large number of 
observations with an EQ5D-5L at 0.942, 0.924 and 0.866, associated with slight problems with 
anxiety and depression and/or pain and discomfort.  
Table 1: Sample summary statistics 
 Mean 
(std. dev.) 
Min Max 
AQLQ-S 0.7085 
(0.7766) 
0 4 
EQ5D-5L 0.8425 
(0.1693) 
-0.073 1 
HUI3 0.7560 
(0.2408) 
-0.1958 1 
Age (years) 43.03 
(15.00) 
18 89 
Country Number of observations 
(%) 
  
1 141 
(16.55) 
- - 
2 150 
(17.61) 
- - 
3 150 
(17.61) 
- - 
4 138 
(16.20) 
- - 
5 126 
(14.79) 
- - 
6 147 
(17.25) 
- - 
AQLQ-S: Asthma quality of life questionnaire-Sydney, EQ5D-5L: EuroQol 5-dimension 5-level questionnaire, HUI3: 
Health utilities index mark 3. 
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Table 2: Model specifications and model choice criteria (n=852) 
# 
component
s 
specification 
Log-
likelihoo
d 
# 
param RMSE MAE ME AIC BIC 
EQ5D-5L Betamix 
3 Probability mass at full health 527.68 33 0.1430 0.1001 -0.0003 -989.36 -832.69 
3 
Probability mass 
at full health 
and truncation 
point 
436.00 38 0.1425 0.1003 0.0005 -796.00 -615.59 
4 Probability mass at full health 538.87 44 0.1429 0.1002 0.0003 -989.75 -780.86 
4¥ 
Probability mass 
at full health 
and truncation 
point 
401.81 45 0.1474 0.1018 -0.0012 -713.62 -499.98 
EQ5D-5L ALDVMM 
3 Bounded 322.42 28 0.1439 0.1006 0.0003 -588.84 -455.90 
4 Bounded 336.64 39 0.1439 0.1004 0.00003 -595.28 -410.13 
HUI3 Betamix 
3 Probability mass at full health 708.05 33 0.2081 0.1566 0.0018 -1350.09 -1193.42 
3 
Probability mass 
at full health 
and truncation 
point 
207.64 38 0.2081 0.1563 0.0024 -339.28 -158.88 
4 Probability mass at full health 727.92 44 0.2076 0.1562 0.0017 -1367.80 -1158.95 
4 
Probability mass 
at full health 
and truncation 
point 
224.48 49 0.2067 0.1548 0.0009 -350.96 -118.33 
HUI3 ALDVMM 
3 Age included 192.51 28 0.2076 0.1556 0.00041 -329.03 -196.10 
4 Age included 212.42 39 0.2071 0.1550 0.00033 -346.85 -161.69 
3 
No age in 
probability 
variables 𝑥𝑥2 
189.87 24 0.2082 0.1563 0.00054 -331.75 -217.80 
4 
No age in 
probability 
variables 𝑥𝑥2 
201.09 33 0.2082 0.1563 0.00026 -336.18 -179.51 
RMSE = Root Mean Squared Error, MAE = Mean Absolute Error, ME = Mean Error, AIC = Akaike Information Criterion, 
BIC = Bayesian Information Criterion.  All models outlined here include a truncation at the best possible health state other 
than full health.  ¥This model would not converge with the AQLQ score in the probabilities parameters. The results presented 
here are for a model without AQLQ in the probabilities. 
 
EQ5D-5L 
We found that models which formally included the gap between full health and the next feasible value 
outperformed those that did not, using both ALDVMM and beta-base mixture models. We therefore 
concentrate on comparing alternative specifications of models that included this gap.  Beta mixture 
models required a specified probability mass at full health in order to ensure they estimated the 
correct proportion of observations at full health.  Table 2 shows model performance criteria for 3 and 
4 component models, each with inclusion of truncation, a mass point at full health and with and 
without a further probability mass at the truncation point (0.951).   Differences in measures of “error” 
between 3 and 4 component models were small, with BIC lower for the 3 component model(14).  The 
model which does not include a probability mass at the truncation point appears to better predict the 
lower end of the EQ5D distribution.  This can be seen in the conditional distribution function graphs 
in Figure 2a and the plots of mean predicted versus observed fit in Figure 3a.  This is because there 
are a relatively small number observations at the truncation point but a large proportion of 
observations at the value just below the truncation point (13.73% at 0.944).  If this spike in 
observations were at the truncation point itself, the model which included a probability mass at the 
truncation point might have shown better fit.  For these reasons, the optimal beta-based model has 3 
components and a probability mass at full health but not at the truncation point.   
Figure 2a: Conditional Distribution Functions for models Estimating EQ5D-5L with betamix 
(observed vs simulated data (1,000 observations)) 
  
3 component betamix model for EQ5D-5L with truncation 
and probability mass at full health 
3 component betamix model for EQ5D-5L with truncation 
and probability mass at full health and truncation point 
 
Figure 2b: Conditional Distribution Functions for models Estimating EQ5D-5L with 
ALDVMMs (observed vs simulated data (1,000 observations)) 
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Figure 3a:  Mean Fit vs Mean Observed PBM by AQLQ for models Estimating EQ5D-5L with 
betamix 
  
3 component betamix model for EQ5D-5L with truncation 
and probability mass at full health 
3 component betamix model for EQ5D-5L with truncation 
and probability mass at full health and truncation point 
 
Figure 3b:  Mean Fit vs Mean Observed PBM by AQLQ for models Estimating EQ5D-5L with 
ALDVMM 
 
  
3 component ALDVMM for EQ5D-5L with truncation 4 component ALDVMM for EQ5D-5L with truncation 
 
Results for 3 and 4 component ALDVMMs are shown in Table 2. The 4 class model offers 
improvements in RMSE, MAE and ME but has a higher BIC. Figures 2b and 3b show that both 
models fit the data closely, suggesting the 3 component model is preferred. Figure 2b shows some 
disparity between the distribution from the model and the data at the upper end of EQ5D-5L. This 
occurs not at the full health value (the data has 21% of observations here compared to 24% in the 
simulated data in the models) but at values just below the truncation point.  
HUI3 
As with EQ5D-5L, we found that models which formally included the gap between full health and the 
next feasible value were preferred to those which did not, having a much lower AIC and BIC. This 
applied to the beta-based mixture model and ALDVMM.  
Beta-based models without a probability mass at full health had difficulty fitting the correct number of 
observations at this value and so we only report models which explicitly modelled this gap and 
include a probability mass at full health.  The model which consistently produced the smallest errors 
was the 4 component model with probability masses at full health and at the truncation point (0.973).  
However, although AIC suggested that the fourth component is beneficial, BIC suggests that 3 
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components is preferred.  The simulated graphs in Figure 4a and the plots of the means in Figure 5a 
show a clear improvement in the model with the additional fourth component, particularly towards the 
lower end of the HUI3 distribution.  We consider the 4 component model to be the optimal beta 
mixture model. 
Figure 4a: Conditional Distribution Functions for models Estimating HUI3 with betamix 
(observed vs simulated data (1,000 observations)) 
  
3 component betamix model for HUI3 with truncation and 
probability mass at full health only and truncation point 
4 component betamix model for HUI3 with truncation and 
probability mass at full health and truncation point  
 
Figure 4b: Conditional Distribution Functions for models Estimating HUI3 with ALDVMM 
(observed vs simulated data (1,000 observations)) 
  
3 component ALDVMM for HUI3 with truncation 4 component ALDVMM for HUI3 with truncation 
 
 
As with the beta mixture models, 4 component ALDVMMs produced lower errors than 3 component 
equivalents.  In all ALDVMMs estimating HUI3, the coefficients for the variables influencing 
component membership were statistically insignificant: for example age had p-values all in excess of 
0.03.  We therefore investigated the use of different variables to predict component membership.  
Results are displayed in Table 2 for models which do not include age to predict component 
probabilities as well as those which do.  Whilst AIC and BIC generally favour the exclusion of age, 
other measures of error are worse. Figures 4b and 5b show a marked difference between these models, 
and suggest that age should remain an explanatory variable for the probabilities because they 
considerably improve the fit of the model.  The evidence indicates that the observed statistical 
insignificance associated with age may be related to the limited sample size.   
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All models have the expected sign and produce simulated data which is a good prediction of the 
sample data.  The estimated coefficients for the 4 preferred models are displayed in the web appendix 
along with a Stata .do file which allows users to enter their own data to predict EQ5D-5L and HUI3 
using these preferred models. 
Figure 5a:  Mean Fit vs Mean Observed PBM by AQLQ for models Estimating HUI3 using 
betamix 
  
3 component betamix model for HUI3 with truncation and 
probability mass at full health and truncation point 
4 component betamix model for HUI3 with truncation and 
probability mass at full health and truncation point  
 
Figure 5b:  Mean Fit vs Mean Observed PBM by AQLQ for models Estimating HUI3 using 
ALDVMM 
  
4 component ALDVMM for HUI3 with truncation 4 component ALDVMM for HUI3 with truncation (age 
removed from probability variables 𝑥𝑥2) 
 
DISCUSSION 
We compared different mapping methods using data collected from people with asthma. Both EQ5D-
5L and HUI3 were considered as target utility instruments, from the AQLQ-S. We focussed on direct 
mapping methods because response-mapping was not feasible in this sample, for either instrument. A 
move to EQ5D-5L, compared to EQ5D-3L, is likely to reduce the feasibility of applying response-
mapping in future, since data samples will more often fail to span all the levels described in the more 
detailed descriptive system.  
Beta-based mixture models and ALDVMMs were estimated. Within these classes of model-type we 
compared different numbers of components in the mixture models with and without a specified gap 
between full health and the next feasible value. For the beta based models, where the gap was 
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specified, we also considered whether there needed to be a specified probability mass at the truncation 
point.   
Models with truncation to create a gap between full health and the next feasible value were 
universally preferred. This gap is part of the “bespoke” nature of both the ALDVMM and the beta-
based mixture model and, whilst the importance of the method has been demonstrated in several 
studies using EQ5D-3L(14), the gap is more pronounced in that instrument (0.12). This contrasts with 
0.049 and 0.027 in the EQ5D-5L and the HUI respectively.  The next largest gap between feasible 
values is 0.024 in EQ5D-5L and 0.027 in HUI3.  To our knowledge no mapping study which uses a 
mixture of beta distributions has accounted for the gap between full health and the next feasible utility 
value.  We find that it remains important for mapping models to explicitly reflect this characteristic of 
utility instruments, even when the gap is relatively small.  Others have claimed the gap is sufficiently 
small not to warrant formal inclusion in the model(5).  Furthermore, the finding is relevant to all 
mapping methods and not simply those that utilise mixture model approaches.    
Beta regression mixture models were identified that better fitted both EQ5D-5L and HUI3 than 
ALDVMMs. Preferred models allowed an inflated number of observations at the next feasible value 
below full health. This feature adds further flexibility to the models but caution needs to be exercised 
in interpreting this finding. Theoretically, the addition of a mass point to the beta model is similar to 
adding an additional component to the ALDVMM. In this sense, the beta mixture approach is more 
artificial than the ALDVMM and comparisons between models with the same number of components 
are not necessarily comparisons of like-with-like. The addition of mass points at selected points in the 
distribution does offer a means to improve fit but this requires the addition of more parameters 
compared and is also less generalizable: there is a risk of over fitting to the data. In general we would 
recommend caution in the inclusion of probability masses at ANY point in the distribution without 
some theoretical rather than empirical justification for doing so: by ‘theoretical justification’ we mean 
that one is clear why such peaks may be relevant, for example the nature of the disease leads to 
bunching at a certain health state utility value. The increased number of parameters required by the 
beta-based mixture model means that for smaller datasets there is a danger that it might be more 
difficult to identify.  For example, we attempted to estimate EQ5D-5L using a four component model 
with probability masses at full health and the truncation point, but this model would not converge 
when AQLQ-S was included in the component membership probabilities.  To reduce the number of 
parameters, we estimated a model without AQLQ-S in the probabilities and achieved a much worse fit 
as a result. 
Our results show the importance of considering the distribution when choosing the most appropriate 
model.  The proportion of observations at the truncation point in a sample should be considered when 
choosing a model, in particular when using the beta-based mixture model.  We found that where there 
were lots of observations at the truncation point (as with HUI3) then a probability mass needed 
including at the truncation point.  The inclusion of this probability mass did not improve the model for 
EQ5D-5L which had very few observations at the truncation point.  However, as discussed above, 
theoretical justification is needed to determine whether these probability masses are generalizable.  
We do not know if this is generalizable to all applications of HUI3 and EQ5D-5L in asthma patients 
or specific to this sample.  Further research is needed to determine the extent to which these results 
are generalizable. 
Other studies have been conducted using asthma outcomes.  Tsuchyia et al estimated EQ5D-3L from 
the less commonly reported 32-item AQLQ-McMaster score(26).  As well as direct mapping using a 
linear regression, this study also carried out the first response-mapping we are aware of. Our results 
are not directly comparable with this study because the AQLQ scores differ.  We are able to compare 
out results to Kaambwa et al who used the same data as in our study. Kaambwa et al. mapped AQLQ-
S onto both EQ5D-5L and HUI3, among other health state utilities(5) using data from the MIC. The 
mixture models reported here outperformed every equivalent model reported by Kaambwa et al; that 
is all models which used the AQLQ-S summary score as an explanatory variable, using the measures 
of model fit describe earlier.    They used four simple methods: ordinary least squares (OLS), 
censored least absolute deviations (CLAD), generalised linear model (GLM) and a beta binomial 
(BB) regression model.   
Mixture models are much more flexible than typically used mapping models. The methods we test 
constrain model outputs to the feasible range between full health and the worst health state, with the 
ability to have large masses at the extremes. Modelling the gap between full health and the next 
feasible health state adds additional flexibility and further restricts outputs to the feasible range for the 
utility instrument. When using these more complex models it is important to consider the 
characteristics of the data and to search for the most appropriate model, both through using different 
specifications of the models, but also ensuring that the global maximum likelihood is found(27).  In 
our search for a global maximum, we found other maxima which included mass points at the top of 
the distribution.  This predicted the number of observations in full health very well but the overall fit 
was much worse and the graphs for the means showed clear misspecification.  
Our results show that each of the chosen models is an improvement on more traditionally used linear 
predictions. Both types of mixture model used in this study are able to closely fit the data without the 
biased performance characteristic of many commonly employed mapping approaches. The beta-based 
mixture models outperformed the ALDVMM models but at the expense of increasing the number of 
parameters as well as estimation time.  Skilled judgment is critical in determining the optimal model. 
Caution is required in ensuring a truly global maximum likelihood has been identified.  
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